Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Alcohol isopropílico inhalado para el tratamiento de las náuseas

21 de septiembre de 2026 actualizado por: Susana Ruano, State University of New York at Buffalo

Alcohol isopropílico inhalado para el tratamiento de las náuseas en un departamento de emergencias pediátricas: un ensayo clínico controlado, aleatorizado y abierto

To determine the efficacy of inhaled isopropyl alcohol in treating nausea/vomiting among pediatric patients compared with the conventional ondansetron, or placebo treatment in a tertiary care pediatric emergency department.

Descripción general del estudio

Descripción detallada

I. Obtaining consent Our study personnel will approach the treating physician in the ED once a patient is suspected to be eligible for the study. The physician will determine patient's eligibility by using the screening sheet. If a patient meets all study inclusion and exclusion criteria, our study personnel will approach the legal guardian/patient in the private patient room and introduce the study to them. Enough time will be given to the patient and their legal guardian to allow them review and understand the consent/assent. All questions will be answered before obtaining the consent. Once the consent/assent is obtained from the legal guardian and participant, our study personnel will keep the treating physician and bedside nurse posted about the enrollment.

II. Randomization of subject

There will be three arms of this study:

  1. Conventional oral ondansetron (Zofran) treatment group,
  2. Inhaled isopropyl alcohol treatment group,
  3. Inhaled normal saline (placebo) group. After obtaining informed consent, the patients will be randomized into one of the three groups following a randomization table created by a statistician.

Whichever intervention is randomly selected will be used to treat the subject. Our research team member will notify the treating physician and the bedside RN about the assignment.

If the subject is assigned to receive ondansetron treatment, subject will be provided with 4 mg ondansetron oral disintegrating tablet (ODT) for treatment.

If the subject is assigned to receive the isopropyl alcohol pad group, an isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) will be given to the subject, or the legal guardian . The alcohol pad will be held 1-2 cm under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed during the ED stay.

If the subject is assigned to receive the inhaled placebo, a normal saline pad (Hygea sterile saline wipe) will be given to the subject or the legal guardian. The saline wipe will be held under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed.

For those subject who receives normal saline or alcohol pad treatment, if their vomit/nausea symptoms has not improvement after 30 minutes post intervention, they may receive Zofran treatment in the ED.

III. Data collection A paper data collection form will be used to collect data in the ED, which is attached with this submission. Patient ID sticker with name, MRN, FIN, and DOB will be placed on the data form. This data form will be completed by the ED research assistant. The completed data form as well as the signed informed consent document will be placed in a locked study data box in the ED. The study coordinator will collect these documents from the ED periodically, and transfer the documents to the UBMD Pediatrics Department Research Office (5th Floor Conventus, 1001 Main St, Buffalo, NY 14203). All paper documents will be stored in locked file cabinet in the office.

Two databases will be created for this study, the Subject Database and the PHI database. Subject identifiable information will be entered in the PHI database, which include: MRN, FIN, and DOB. All other data elements will be entered in the Subject Database. Certain PHI e.g. ED visit/discharge date, study intervention administration date will also be entered in the Subject database for the convenience of data analysis. A unique study ID will be assigned to each subject, this ID number will be used as the code key to link the paper data form, Subject Database and PHI database. Both databases will be saved in study coordinator's password protected UPA online drive, the PHI database will be double secured by a code.

Data Collection:

  1. Demographic data: Patient age, sex, race, and ethnicity

  2. Baxter Animated Retching Faces nausea score at: Baseline (prior to intervention), 10 minutes post-intervention, 30 minutes post-intervention, and at ED discharge.

    The 10 minute post-intervention timepoint was selected because prior research in adult post-operative patients has shown that inhaled isopropyl alcohol significantly improved nausea on surveys conducted 5, 10, and 15 minute after inhalation.6 The 30 minute post-intervention timepoint was selected because the onset of action for ondansetron oral disintegrated tablet is within 30 minutes.132 We will reassess nausea symptoms at ED discharge to account for any anti-emetic benefit that may have only be transient.

  3. ED clinical information about vomiting and apparent aspiration

  4. Patient/caregiver perceived side effects of treatment

  5. Satisfaction scores: From both the bedside nurse and the patient's caregiver

  6. Cross-over information: Did the patient use a treatment other than the assigned treatment (e.g. if the patient was in the inhaled isopropyl alcohol group, did they cross-over into the ondansetron ODT group)

  7. ED discharge information: Length of stay, patient disposition and discharge diagnosis

Tipo de estudio

Intervencionista

Inscripción (Estimado)

84

Fase

  • Fase 2
  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Haiping Qiao, MBBS, MS
  • Número de teléfono: 7163230055
  • Correo electrónico: hqiao@upa.chob.edu

Copia de seguridad de contactos de estudio

  • Nombre: Alana Koehler, MD
  • Número de teléfono: 315576264
  • Correo electrónico: alanakoe@buffalo.edu

Ubicaciones de estudio

    • New York
      • Buffalo, New York, Estados Unidos, 14203
        • Reclutamiento
        • Oishei Children's Hospital
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

7 años a 17 años (Niño)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients with a chief complaint of nausea or vomiting
  • Ages 7-178 years, both sexes
  • Weight ≥ 15 kg
  • Baxter Animated Retching Faces (BARF) nausea severity score ≥ 4/10

Exclusion Criteria:

  • 1. Require IV access
  • Inability to breathe in/out through the nose
  • Anosmia (self- or parental report)
  • Allergy to isopropyl alcohol or ondansetron
  • Current or history of alcohol abuse
  • Inability to communicate feeling nauseous
  • Inability to follow directions regarding taking deep breaths through the nose
  • Known prolonged QT interval
  • Pregnancy
  • Received antiemetics within the last 8 hours
  • Currently taking apomorphine

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Inhaled Isopropyl Alcohol

If the subject is assigned to receive the isopropyl alcohol pad group, an isopropyl alcohol pad (Covidien Webcol 2 ply prep pad, saturated with 70% isopropyl alcohol) will be given to the subject, or the legal guardian. The alcohol pad will be held 1-2 cm under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed during the Emergency Department (ED) stay.

Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares

Otros nombres:
  • Webcol
Comparador activo: Oral Ondansetron

If the subject is assigned to receive ondansetron treatment, subject will be provided with 4 mg ondansetron oral disintegrating tablet (ODT) for treatment.

4 mg oral disintegrating ondansetron tablet once

Otros nombres:
  • Zofran
Comparador de placebos: Inhaled Placebo

If the subject is assigned to receive the inhaled placebo, a normal saline pad (Hygea sterile saline wipe) will be given to the subject or the legal guardian. The saline wipe will be held under the subject's nares, the subject will be instructed to take deep breaths, inhaling through the nose as frequently as needed.

Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares

Otros nombres:
  • Solución salina normal inhalada

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Nausea Score at 30 Minutes
Periodo de tiempo: 30 minutes post-intervention as compared to baseline

Baxter Animated Retching Faces nausea score, 0-10 with higher score meaning worse nausea

30 minutes post-intervention as compared to baseline
Change in Nausea Score at 10 Minutes
Periodo de tiempo: 10 minutes post-interventnon as compared to baseline

Baxter Animated Retching Faces nausea score, 0-10 with higher score meaning worse nausea

10 minutes post-interventnon as compared to baseline
Change in Nausea Score at Discharge
Periodo de tiempo: At ED discharge (assessed up to 10 hours) as compared to baseline

Baxter Animated Retching Faces nausea score, 0-10 with higher score meaning worse nausea

At ED discharge (assessed up to 10 hours) as compared to baseline

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Vomiting
Periodo de tiempo: From intervention to time of ED discharge (assessed up to 10 hours)

Number of episodes of vomiting post-intervention

From intervention to time of ED discharge (assessed up to 10 hours)
Parent/Caregiver Satisfaction
Periodo de tiempo: At time of ED discharge (assessed up to 10 hours)

Patient's parent/caregiver satisfaction score (very dissatisfied, dissatisfied, neutral, satisfied, very satisfied)

At time of ED discharge (assessed up to 10 hours)
Nurse Satisfaction in Ease of Administering the Treatment
Periodo de tiempo: At time of ED discharge (assessed up to 10 hours)

Patient's bedside nurse satisfaction score (very difficult, somewhat difficult, neutral, somewhat easy, very easy)

At time of ED discharge (assessed up to 10 hours)
Length of Stay
Periodo de tiempo: From arrival to time of ED discharge (assessed up to 10 hours)

Length of patient's stay in the emergency department

From arrival to time of ED discharge (assessed up to 10 hours)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Alana Koehler, MD, SUNY Buffalo
  • Director de estudio: Heather Territo, MD, SUNY Buffalo

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de abril de 2022

Finalización primaria (Estimado)

30 de junio de 2027

Finalización del estudio (Estimado)

30 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

1 de junio de 2022

Primero enviado que cumplió con los criterios de control de calidad

12 de junio de 2022

Publicado por primera vez (Actual)

14 de junio de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de octubre de 2025

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir